Sarah M. Paul - Oncology Biomarker Development, Genentech

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 26 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Abstract 1295: CancerCare Coping Circle Workshop for Patients with Cancer and Covid-19

Christine Verini,Sarah Paul, Rebecca Ashkenazy, Brittany Wolf Gianares

Cancer Researchno. 6_Supplement (2024): 1295-1295

引用0浏览0引用

Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non–Small Cell Lung Cancer: Results from the Randomized OAK Trial

Shirish Gadgeel,Fred R. Hirsch,Keith Kerr,Fabrice Barlesi,Keunchil Park,Achim Rittmeyer,Wei Zou, Namrata Bhatia,Hartmut Koeppen,Sarah M. Paul,David Shames,Jing Yi,Christina Matheny,Marcus Ballinger,Mark McCleland,David R. Gandara

Clinical lung cancer（2022）

引用8浏览0WOS引用

Clinicogenomic Real-World Data Analysis of Patients (pts) with KRAS G12C-mutant Advanced Non-Small Cell Lung Cancer (ansclc) from the Natural History Cohort of the Blood First Assay Screening Trial (BFAST)

Rafal Dziadziuszko,Xiao Li, Eric C. Anderson,Alona Zer,Luis Corrales-Rodriguez,Parneet Cheema,Aleksandra Szczesna,Manuel Philco,Michael Mathisen,Sarah M. Paul, Vijay Bhagawati-Prasad,Gaurav Pathria,Zhen Shi,Magalie Hilton,Qing Zhang

Journal of clinical oncology（2021）

引用0浏览0引用

1301P Blood First Assay Screening Trial (BFAST) in Patients (pts) with 1L NSCLC: ALK+ Cohort Updated Biomarker Analyses

S. M. Gadgeel,M. Yan,S. M. Paul,M. Mathisen,S. Mocci,Z. J. Assaf,R. Patel,E. S. Sokol,T. Mok,S. Peters,L. Paz-Ares,R. Dziadziuszko

Annals of oncology（2020）

引用1浏览0引用

1307P Blood-based Genomic Profiling of Advanced Non-Small Cell Lung Cancer (ansclc) Patients (pts) from Blood First Assay Screening Trial (BFAST) and Comparison with Real-World Data (RWD)

R. Dziadziuszko, Q. Zhang,X. Li,S. M. Paul,M. Sugidono,S. Mocci, A. Kinkolykh,D. S. Shames,V. Archer,M. S. Mathisen,D. X. Jin,S. M. Gadgeel,S. Peters,T. Mok

Annals of oncology（2020）

引用2浏览0引用

Exploratory subgroup analysis of atezolizumab (atezo) clinical characteristics in patients (pts) with low circulating tumor DNA (ctDNA) in B-F1RST-a Phase II trial evaluating blood-based tumor mutational burden (bTMB) in NSCLC

Mark A. Socinski,Sarah M. Paul,Cindy Yun,Sylvia Hu,Vincent Shen, Vamsidar Velcheti,Tony S. Mok,David R. Gandara,Young Kwang Chae,Erica Schleifman,David A. Fabrizio, David S. Shames,See Phan,Edward S. Kim

CANCER RESEARCH（2019）

引用5浏览0引用

Abstract CT194: Exploratory subgroup analysis of atezolizumab (atezo) clinical characteristics in patients (pts) with low circulating tumor DNA (ctDNA) in B-F1RST—a Phase II trial evaluating blood-based tumor mutational burden (bTMB) in NSCLC

Mark A. Socinski,Sarah M. Paul,Cindy Yun,Sylvia Hu,Vincent Shen, Vamsidar Velcheti,Tony S. Mok,David R. Gandara,Young Kwang Chae,Erica Schleifman, David A. Fabrizio,David S. Shames,See Phan,Edward S. Kim

Clinical Trials（2019）

引用5浏览0引用

Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC: Initial results from the ALK+ cohort

S.M. Gadgeel,T.S.K. Mok, S. Peters, J.A.A. Alexander,N.B. Leighl,V. Sriuranpong,M. Perol,G. De Castro,E. Nadal,F. De Marinis,J.-Y. Han, M. Yan,T. Riehl,E. Schleifman,S.M. Paul,S. Mocci, D. Shames,M.S. Mathisen,R. Dziadziuszko

Annals of Oncology (2019): v918

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn